I just got a weed-infused massage, and I feel GREAT


Each eight-ounce bottle of Apothecanna’s Pain Cream sells for around $45 and includes 240 milligrams of cannabis extracts, “approximately 80 percent THC and 4 percent CBD,” said Apothecanna founder James Kennedy. His products are “flying off the shelves” at various Colorado pot shops, he said, and he’s also thrilled with his current collaboration with LoDo Massage owner Ed Rich, who noted that the newly introduced Mile High Therapeutic Massage, normally $75/hour, is on a $65/hour special through the end of July at their studio at 3101 Walnut St.

Increased Demand for CBD Epilepsy Treatment


The University of Alabama is currently playing the waiting game as it seeks approval from the FDA on its ability to initiate research and development on CBD oils in relation to pain suppression and epileptic treatment. Merely a few months ago, the University was given approval by the Alabama State Legislature in the form of a 5-year, $1 million research grant, leaving Federal law as the only stumbling block towards progress.  Roughly 80 days have come and gone without the university hearing back from the FDA.


3-Year-Old Girl Dies Waiting for Tennessee’s Cannabis Oil


12/13/2014, FDA Approves Cannabidiol Study at University of Alabama

Although UAB was given permission to commence their research, Shepard says the FDA requested some amendments to the legislation, which is slated to be brought before the university review board in January.

JAMA report from University of Colorado ER


The Journal of the American Medical Association has published a report penned by three emergency room physicians at the University of Colorado hospital in Aurora about the health-related fallout from marijuana legalization in the state…

“Marijuana may have a safer therapeutic window than opioids for pain control, and an observational study found fewer opioid-related deaths in states with liberal marijuana laws.”

Understanding the Limitations of Drug Test Information Reporting…

…and Testing Practices in Fatal Crashes

by the U.S. Dept. of Transportation

National Highway Traffic Safety Administration

November 2014

Click to access 812072.pdf

There is no consistent policy or set of procedures between, or sometimes even within, States for drug testing. Considerable variation exists regarding who is tested; which drug is tested for; type of test, cut-off levels, and equipment; and which biological specimen (blood, urine, or oral fluid) is used.

Jurisdictions (or labs within a jurisdiction) may vary also regarding the sensitivity of their tests and their “cut-off” levels for indicating the presence of a drug. Testing for drugs involves performing screening tests (which are less expensive and less sensitive), and confirmatory tests. Some laboratories do not consistently perform both types of tests, even when they are appropriate.

Caution should be exercised in assuming that drug presence implies driver impairment. Drug tests do not necessarily indicate current impairment. Also, in some cases, drug presence can be detected for a period of days or weeks after ingestion….

These facts, plus the information presented above, demonstrate that we cannot infer whether drugged driving has increased; similarly we cannot know the extent to which drugged driving differs across States.